Views

CrossRef citations to date

Altmetric

Letters to the Editor

Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG)

Elżbieta Iskierka-JażdżewskaDepartment of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland;

Marek HusDepartment of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland;

Krzysztof GiannopoulosExperimental Hematooncology Department, Medical University of Lublin & Hematology Department, St. John's Cancer Center, Lublin, Poland;

Elżbieta MądroDepartment of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland;

Jadwiga HołojdaDepartment of Hematology, Specialist District Hospital, Legnica, Poland;

Magdalena PiotrowskaDepartment of Hematology, Cracow University Hospital, Cracow, Poland;

Jan M. ZauchaDepartment of Oncological Propaedeutics, Medical University of Gdansk, Gdansk, Poland & Gdynia Oncology Center, Gdynia, Poland;

Weronika PiszczekDepartment of Hematology, Copernicus Hospital, Torun, Poland;

Agnieszka SzeremetDepartment of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland;

Małgorzata WojciechowskaDepartment of Hematology, Specialist District Hospital, Olsztyn, Poland;

Paweł SteckiewiczDepartment of Hematology, Holycross Cancer Center, Kielce, Poland;

Wanda Knopińska-PosłusznyDepartment of Hematology, Independent Public Health Care of the Ministry of the Internal Affairs with the Oncology Centre, Olsztyn, Poland;

Marek OsowieckiDepartment of Lymphoid Malignancies, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warsaw, Poland;

Joanna Drozd-SokołowskaDepartment of Hematology, Oncology and Internal Diseases, Medical University of Warsaw, Warsaw, Poland;

Beata KumiegaDepartment of Haematooncology, Oncology Centre of the Podkarpackie Province, Brzozow, Poland;

Sławomira Kyrcz-KrzemieńDepartment of Hematology and Bone Marrow Transplantation, Silesian Medical University Hospital SPSKM, Katowice, Poland;

Janusz HałkaDepartment of Hematology, Military Institute of Medicine, Warsaw, Poland;

Marek DudzińskiDepartment of Hematology, Specialist District Hospital, Rzeszow, Poland;

Paulina WieszczyDepartment of Gastroenterology, Hepatology and Clinical Oncology, Medical Center for Postgraduate Education, Warsaw, Poland

Tadeusz RobakDepartment of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland;

Krzysztof WarzochaDepartment of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland;

Krzysztof JamroziakDepartment of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland; Correspondence[email protected]

show all

References

Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213–223.
PubMed Web of Science ®Google Scholar
Winqvist M, Asklid A, Andersson PO, et al. Real-world results of ibrutinib in patients with relapsed and refractory chronic lymphocytoc leukemia: Data from 95 consecutive patients treated in compasionate use program. Haematologica. 2016;101(12):1573–1580.
PubMed Web of Science ®Google Scholar
Hallek M, Cheson BD, Catovsky D, et al. International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(9): 4446–4556.
PubMed Web of Science ®Google Scholar
Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125:2497–2506.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG)

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG)

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date